The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis.
The retinoic acid receptor beta2(RARβ2) is a type of nuclear receptor that is activated by both all-trans retinoic acid and 9-cis retinoic acid, which has been shown to function as a tumor suppressor gene in different types of human tumors. Previous reports demonstrated that the frequency of RARβ2 m...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23675444/?tool=EBI |
id |
doaj-9b7288552124475d8ec860b6b88567a1 |
---|---|
record_format |
Article |
spelling |
doaj-9b7288552124475d8ec860b6b88567a12021-03-03T20:23:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0185e6295010.1371/journal.pone.0062950The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis.Tianyi GaoBangshun HeYuqin PanRui LiYeqiong XuLiping ChenZhenling NieLing GuShukui WangThe retinoic acid receptor beta2(RARβ2) is a type of nuclear receptor that is activated by both all-trans retinoic acid and 9-cis retinoic acid, which has been shown to function as a tumor suppressor gene in different types of human tumors. Previous reports demonstrated that the frequency of RARβ2 methylation was significantly higher in prostate cancer patients compared with controls, but the relationship between RARβ2 promoter methylation and pathological stage or Gleason score of prostate cancer remained controversial. Therefore, a meta-analysis of published studies investigating the effects of RARβ2 methylation status in prostate cancer occurrence and association with both pathological stage and Gleason score in prostate cancer was performed in the study. A total of 12 eligible studies involving 777 cases and 404 controls were included in the pooled analyses. Under the random-effects model, the pooled OR of RARβ2 methylation in prostate cancer patients, compared to non-cancer controls, was 17.62 with 95%CI = 6.30-49.28. The pooled OR with the fixed-effects model of pathological stage in RASSF1A methylated patients, compared to unmethylated patients, was 0.67 (95%CI = 0.40-1.09) and the pooled OR of low-GS in RARβ2 methylated patients by the random-effect model, compared to high-GS RARβ2 methylated patients, was 0.54 (95%CI = 0.28-1.04). This study showed that RARβ2 might be a potential biomarker in prostate cancer prevention and diagnosis. The detection of RARβ2 methylation in urine or serum is a potential non-invasive diagnostic tool in prostate cancer. The present findings also require confirmation through adequately designed prospective studies.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23675444/?tool=EBI |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tianyi Gao Bangshun He Yuqin Pan Rui Li Yeqiong Xu Liping Chen Zhenling Nie Ling Gu Shukui Wang |
spellingShingle |
Tianyi Gao Bangshun He Yuqin Pan Rui Li Yeqiong Xu Liping Chen Zhenling Nie Ling Gu Shukui Wang The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. PLoS ONE |
author_facet |
Tianyi Gao Bangshun He Yuqin Pan Rui Li Yeqiong Xu Liping Chen Zhenling Nie Ling Gu Shukui Wang |
author_sort |
Tianyi Gao |
title |
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. |
title_short |
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. |
title_full |
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. |
title_fullStr |
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. |
title_full_unstemmed |
The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. |
title_sort |
association of retinoic acid receptor beta2(rarβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
The retinoic acid receptor beta2(RARβ2) is a type of nuclear receptor that is activated by both all-trans retinoic acid and 9-cis retinoic acid, which has been shown to function as a tumor suppressor gene in different types of human tumors. Previous reports demonstrated that the frequency of RARβ2 methylation was significantly higher in prostate cancer patients compared with controls, but the relationship between RARβ2 promoter methylation and pathological stage or Gleason score of prostate cancer remained controversial. Therefore, a meta-analysis of published studies investigating the effects of RARβ2 methylation status in prostate cancer occurrence and association with both pathological stage and Gleason score in prostate cancer was performed in the study. A total of 12 eligible studies involving 777 cases and 404 controls were included in the pooled analyses. Under the random-effects model, the pooled OR of RARβ2 methylation in prostate cancer patients, compared to non-cancer controls, was 17.62 with 95%CI = 6.30-49.28. The pooled OR with the fixed-effects model of pathological stage in RASSF1A methylated patients, compared to unmethylated patients, was 0.67 (95%CI = 0.40-1.09) and the pooled OR of low-GS in RARβ2 methylated patients by the random-effect model, compared to high-GS RARβ2 methylated patients, was 0.54 (95%CI = 0.28-1.04). This study showed that RARβ2 might be a potential biomarker in prostate cancer prevention and diagnosis. The detection of RARβ2 methylation in urine or serum is a potential non-invasive diagnostic tool in prostate cancer. The present findings also require confirmation through adequately designed prospective studies. |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23675444/?tool=EBI |
work_keys_str_mv |
AT tianyigao theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT bangshunhe theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT yuqinpan theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT ruili theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT yeqiongxu theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT lipingchen theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT zhenlingnie theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT linggu theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT shukuiwang theassociationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT tianyigao associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT bangshunhe associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT yuqinpan associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT ruili associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT yeqiongxu associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT lipingchen associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT zhenlingnie associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT linggu associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis AT shukuiwang associationofretinoicacidreceptorbeta2rarb2methylationstatusandprostatecancerriskasystematicreviewandmetaanalysis |
_version_ |
1714822761265758208 |